|This picture, taken on September 9, 2020, shows a test tube labeled with a vaccine in front of the AstraZeneca logo. REUTERS / Dado Ruvic / Illustration|
AstraZeneca said on Thursday that preliminary data from the trial showed that its Covid-19 shot, Waxzavaria, increased antibodies against Omicron and other types when given as a third booster dose.
Increased response to the Delta variant was also seen in the blood analysis of people who had previously been vaccinated with Vaxveria or mRNA, the drug manufacturer said, adding that it would submit the data to regulators around the world, given the urgent need for booster. .
AstraZeneca has developed the vaccine with researchers at Oxford University, and a laboratory study conducted by the university last month found levels of antibodies in the blood against a rapidly spreading omikron variant in a three-dose course of waxavaria.
The brief statement on Thursday, which did not include specific data, was the first by AstraZeneca as a booster shot after an MRNA-based vaccine or a two-shot course of Vaxavaria on the protective potential of Vaxavaria. Vaccines based on mRNA technology are manufactured by BioNTech-Pfizer and Moderna.
The company said the findings “add to the growing group of evidence supporting Waxzavaria as a third dose booster regardless of the initial vaccination schedule.”
Data on the potential of waxavaria as a booster came from comparative analysis in a redesigned vaccine trial that uses vector technology behind waxavaria but now targets advanced beta variants. AstraZeneca is trying to show that beta-specific vaccines have potential against other types and more trial data is expected during the first half of the year.
Separately, Oxford University and AstraZeneca began work last month on a vaccine specifically targeting Omicron, although Astra – as well as other vaccine makers in similar development projects – said it was not yet clear whether such an upgrade was needed.
A large British trial in December found that antibodies increased when a shot of AstraZeneca was given as a booster after initial vaccination with its own shot or Pfizer, but that was before the explosive spread of the Omicron variant.
However, studies at the time concluded that mRNA vaccines made by Pfizer and Moderna were most likely to promote antibodies when given as a third dose.
AstraZeneca and its contract manufacturing partners have supplied more than 2.5 billion doses of its vaccine globally, even though it is not approved in the United States, while BioNTech-Pfizer has shipped about 2.6 billion doses.
Source: ARY News